CHB - China Biotech Innovation ETF
Assets | $5.99M |
NAV | $17.10 |
Expense Ratio | 0.65% |
PE Ratio | 125.18 |
Beta (5Y) | 2.15 |
Dividend (ttm) | n/a |
Dividend Yield | n/a |
Ex-Dividend Date | n/a |
1-Year Return | - |
Trading Day | April 21 |
Last Price | $17.63 |
Previous Close | $17.10 |
Change ($) | 0.53 |
Change (%) | 3.09% |
Day's Open | 17.49 |
Day's Range | 17.49 - 17.63 |
Day's Volume | 517 |
52-Week Range | 14.75 - 20.17 |
Fund Description
The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index (underlying index). The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China's biotechnology industry. It is non-diversified.
Asset Class Equity | Inception Date Sep 22, 2020 |
Exchange NASDAQ | Ticker Symbol CHB |
Index Tracked Solactive China Biotech Innovation Index |
Top 10 Holdings
64.41% of assetsName | Symbol | Weight |
---|---|---|
WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S | 2269.HK | 10.48% |
Changchun High and New Technology Industry Group Inc | 000661.SZ | 9.35% |
Walvax Biotechnology Co Ltd | 300142.SZ | 8.04% |
Zai Lab | ZLAB | 7.24% |
BeiGene | BGNE | 7.06% |
Shenzhen Kangtai Biological Products Co Ltd A | 300601.SZ | 5.80% |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A | 300357.SZ | 4.62% |
Sino Biopharmaceutical Ltd | 1177.HK | 4.16% |
Pharma Block Sciences (Nanjing) Inc Class A | 300725.SZ | 3.85% |
BGI Genomics Co Ltd Class A | 300676.SZ | 3.82% |
Investing in biotech stocks may feel daunting to many investors, but these three stocks deserve to be on your watchlist. The post 3 Biotech Stocks With Eye-Catching Pipelines appeared first on InvestorP...
All around the world, economic superpowers are vying to be the first to develop a vaccine for Covid-19. China is an obvious contender given that the country was the epicenter of the virus and their succ...